Oxford Biomedica (OXB) Share Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings or view top-rated stocks.

3 analysts have issued 1 year target prices for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 310 to GBX 1,010. On average, they expect the company's stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.

Oxford Biomedica's stock was trading at GBX 442.50 at the beginning of the year. Since then, OXB shares have decreased by 32.7% and is now trading at GBX 298.
View the best growth stocks for 2023 here.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of OXB stock can currently be purchased for approximately GBX 298.

Oxford Biomedica (LON:OXB) has a market capitalization of £287.87 million and generates £119.02 million in revenue each year. The biopharmaceutical company earns £-61,630,000.00 in net income (profit) each year or GBX (0.66) on an earnings per share basis.

The company employs 894 workers across the globe.

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.